

WA RSV Program 2025: PCH Experience

Professor Asha Bowen OAM

Department of Infectious Diseases, Perth Children's Hospital, Child and Adolescent Health Service

Wesfarmers Centre for Vaccines and Infectious Diseases, The Kids Research Institute, University of Western
Australia




WESFARMERS
CENTRE OF VACCINES
& INFECTIOUS DISEASES



Acknowledgment of Country

The Child and Adolescent Health Service acknowledge Aboriginal people of the many traditional lands and language groups of Western Australia.

We acknowledge the wisdom of Aboriginal Elders both past and present and pay respect to Aboriginal communities of today.



RSV Prevention in 2024

- Nirsevimab program for birth cohort + medically at risk catch up in 2nd year of life
 - Exciting, novel, rapid scale up “Game Changer”
 - Very good coverage, predominantly at birth hospitals
 - Clear messaging
 - Dramatic reduction in hospitalisations in 1st 6 months of life for RSV confirmed in REVIVE cohort
 - VE 88.4% (95% CI 73.5 – 94.7%)¹
 - Coverage 60% (cases), 22% (controls)¹

¹Wadia et al J Infection 2025



RSV Prevention in 2025 in WA

- Maternal Vaccine commenced 3 Feb 2025
 - Funded by Commonwealth via NIP
- Nirsevimab continued from 2024, with season commencing on 1 April – 30 September 2025
 - Funded by WA Health
 - High risk infants, and those whose mother did not receive maternal vaccine in pregnancy (28-36 wks)



2025 Hospital Experience

- Mixed messages with 2 programs
- Potentially diluted impact & coverage
 - Asking about RSV protection less well done on admission to hospital
 - Less focus on catch up or high-risk population
- A noticeable reduction in infants admitted to hospitals with ARI
 - Much needed, as bumper influenza year so still very busy in the hospitals
- VE slightly lower but still very good

